TEVA completes $3bn refinancing

December 19, 2012 12:00 am

TEVA Pharmaceuticals, an Israel-based drug company, signed a new $3bn five year unsecured revolving credit facility on Tuesday that replaces its existing smaller loan.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Syndicated Loans LevFin Leveraged Loans Emerging Market Loans Securitization - CLOs LevFin - CLOs Emerging Markets

Related articles

Leader

Disaster-sensitive bonds are needed, but get them right

The necessity of clauses that help developing countries recover from catastrophes is getting more acute

George Collard, October 30, 2025
Emerging Markets

Jamaica hurricane could spur introduction of disaster 'pause clauses'

Climate-resilient debt clauses exist, but a group is working to roll them out to more emerging market sovereigns

George Collard, October 30, 2025
Southpaw

Basics top the charts: banks scramble to ride infrastructure boom

Physical infrastructure, once seen as boring and ex-growth, has become one of the hottest areas for capital markets and M&A, and that is set to accelerate in 2026

David Rothnie, October 30, 2025
CLOs Europe

Barings prices first European private credit CLO in two currencies

Portfolio consists of 65 loans it had originated

Thomas Hopkins, October 30, 2025
CLOs Europe

People’s Pension puts £260m into CLOs via Invesco

Partnership blends exposure to CLOs and CLO ETFs

Thomas Hopkins, October 30, 2025
Emerging Markets

Ziraat Bank debut AT1 offers premium to peers

Demand for the Turkish bank's deal was about three times the issue size

George Collard, October 30, 2025